Current and emerging therapies in multiple sclerosis: A systematic review

Wanda Castro-Borrero, Donna Graves, Teresa C. Frohman, Angela Bates Flores, Paula Hardeman, Diana Logan, Megan Orchard, Benjamin Greenberg, Elliot Frohman

Research output: Contribution to journalReview articlepeer-review

103 Scopus citations

Abstract

Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

Original languageEnglish (US)
Pages (from-to)205-220
Number of pages16
JournalTherapeutic Advances in Neurological Disorders
Volume5
Issue number4
DOIs
StatePublished - Jul 2012

Keywords

  • disease-modifying therapies
  • emerging therapies
  • fingolimod
  • glatiramer acetate
  • interferon I
  • multiple sclerosis
  • natalizumab

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Current and emerging therapies in multiple sclerosis: A systematic review'. Together they form a unique fingerprint.

Cite this